MLD to attend CTAD 2019

Dr. Shawn Ritchie and Dr. Tara Smith will be in San Diego next week to attend the 12th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. This conference is an opportunity for researchers from around the world to present their findings on the safety and efficacy of novel AD treatments, as well as new biomarkers of disease that could be used to improve trial design. The information gained at this event will be used by MLD as it begins planning a future clinical program for PPI-1011, our lead plasmalogen precursor for AD.